Could a Vitamin-Like pill stop prediabetes from becoming diabetes?

NCT ID NCT07286747

Recruiting now Prevention Sponsor: University Hospital Schleswig-Holstein Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests whether a special form of nicotinic acid (a B vitamin) can reverse prediabetes and prevent type 2 diabetes. About 390 adults with prediabetes will take either a low or high dose of the drug or a placebo daily for 26 weeks, along with lifestyle advice. The goal is to see if the drug can bring blood sugar levels back to a healthy range.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: controlled-ileal-release nicotinic acid (CIR-NA)
What this could lead to: If it works, this could offer a new way to prevent prediabetes from turning into type 2 diabetes, potentially reducing the need for lifelong medication.
What could go wrong: This is a phase II trial, so it's still early. The drug may not work better than placebo, and side effects like flushing or stomach issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREDIABETES (INSULIN RESISTANCE, IMPAIRED GLUCOSE TOLERANCE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glucose intolerance Insulin Resistance prediabetes syndrome type 2 diabetes mellitus prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PREDIABETES (INSULIN RESISTANCE, IMPAIRED GLUCOSE TOLERANCE)

Contacts and locations

Locations

University Medical Center Schleswig-Holstein, Campus Kiel
RECRUITING

Kiel, 24105, Germany
University of Leipzig Medical Center
RECRUITING

Leipzig, 04103, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.